CANONIC

Bringing precision
to medical cannabis

Safe harbor

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

CANONIC

Agenda

**Introduction**   Our technology   Evogene group   Summary

CANONIC

Our mission

To bring to market medical cannabis products with unique genomic profiles for greater cannabinoid Specificity, Yield and Stability.

Key Market challenges

CANNABINOID SPECIFICITY

Specific medical indications require tailored active compound profiles. To date, breeding mainly pushed THC levels

Median retail price per gram cannabis (Oregon)

CANNABINOID YIELD

Legalization is driving steep declines in market prices, giving advantage to high yield products

CANNABINOID STABILITY

Substantial variations within varieties produce inconsistent products and therefore inconsistent results

Tackling market challenges...

Our solution

Based on established world-class genomic expertise and technology we create specific genomic profiles to address market challenges – cannabinoid specificity, yield and stability.

CANONIC

# Our solution

Using computational power (Artificial Intelligence, Big Data) to decode the cannabis genome & identify the specific genomic profiles that overcome market challenges

Current cannabis genetic mapping

THC gene

CBD gene affected

Essential gene

Canonic: seeing the bigger picture

- ● Essential genes
- ● CBD genes
- ● THC genes
- ● Proprietary high yield genes

CANONIC

Cannabis – the optimal crop for our solution

Fact 1

Cannabis has been caught in a time capsule with no access to innovation and technologies

Small intervention - huge impact

Fact 2

Cannabis can be grown for at least 3 growth cycles in a year

Triple development speed

Fact 3

Cannabis is grown in a controlled environment

Consistent performance

Canonic's technology platform enables fast & efficient, non-GMO product development

CANONIC

Go-to-market strategy

Canonic aims to quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing elements of the value chain.

CANONIC — **Specialized growers** — **Sub-contractors**

Activity	Varieties development	Seed production	Seedling production	Cannabis cultivation	Extraction, formulation & distribution	CLIENT
Product		IP	Seeds	Seedlings	Flowers	Formulation

Variety development through advanced breeding, seed production and seedling production, will be conducted in-house, while cultivation, formulation and distribution will be conducted through partnerships.

CANONIC

Product lines under development

Stable enhancement of **total plant** compounds

MetaYield⁺ Unican⁺

Type1: Increased trichomes prevalence
*[increased active compounds per plant]*

Type2: Dwarf - early flowering
[increased yield per area]

Stable enhancement of **specific active** compounds

Precise⁺ Unican⁺

Type1: Increased content of known active compounds [e.g. CBG/CBC]

Type2: Increased content of uncharacterized active compounds [CBx]

Canonic's team

Management

Ofer Haviv
Chairman of the board

Evogene CEO and President

Dr. Arnon Heyman
CEO

Former VP and GM Ag seeds division
Evogene, CTO BondX technologies

Dr. Inbal Dangoor
Head of R&D

Former Biotech Trait Manager,
Ag seeds division Evogene

Advisory board

Dr. Yossi Tam
Cannabinoid clinical research

Director, Multidisciplinary Center for
Cannabinoid Research of the Hebrew university

Dr. Yariv Brotman
Plant metabolic pathways

Senior Lecturer at Ben Gurion University
& Max Planck institute of Molecular Plant Physiology

Dr. Moshe Bar
Plant breeding

Founder and CEO of Biotagate. Previously Global Head of Scouting
and Strategic Projects at Syngenta and VP R&D at Zeraim Gedera

Agenda

Introduction

Our technology

Evogene group

Summary

CANONIC

The Challenge
Product development common practice

Product Definition

✓ Yield

✓ Cannabinoid spec

✓✗ Stability

✗ Safety

✗ Product Launch

Candidates mainly addressing the first criterion

Low probability of success

Long time to market

High development costs

Limited 'next generation' products in pipelines

CANONIC

The desired solution
Candidates with the highest probability of success

Product Definition

✓ Yield

✓ Cannabinoid spec

✓ Stability

✗ Safety

✗ Successful Product Launch

Candidates mainly addressing the first criterion

Candidates addressing the majority of product criteria at Stage Zero

✓ Successful Product Launch

- Increasing probability of success
- Reducing time to market
- Reducing budget

CANONIC

Our solution – the CPB platform

Product Definition

Yield ✓

Cannabinoid spec ✓

Stability ✓✗

Safety ✗

Successful Product Launch ✗

Candidates mainly addressing the first criterion

Evogene CPB platform

evogene
Plant Innovation

Science

Tailored big data

Interconnected data hub

Computational Analysis

Predictive analysis validation

Successful Product Launch ✓

- Increasing probability of success
- Reducing time to market
- Reducing budget

CPB: Computational Predictive Biology platform

CANONIC

Enabling technology (Evogene's CPB)& IP

Canonic holds exclusive access to assets along the entire innovation value chain for improved varieties development

Science - Plant genetics
know how & IP

Tailored data

Interconnected data hub

Computational analysis

Plant validation

Innovation will transform the cultivation, processing, sale, and consumption of cannabis in legal markets (New Frontier data 2019)

CANONIC

Science - Plant genetics know-how & IP

Access to an immense know-how & IP portfolio

### Example - trichrome enhancement

evogene
Plant Innovation

Within the top 10 companies in the world holding plant genetics know how & IP

Proprietary IP portfolio relevant for Cannabis:

- Trichomes
- Growth rate and phenology
- Plant architecture
- Abiotic stress tolerance
- Disease resistance

Cannabinoid concentration is effected by the trichome population

Improved trichomes in tomato by Evogene

Wild type

Modified type

CANONIC

Tailored data

High quality data

- > 200 plant species
- > $3*10^9$ data points
- > 1000 experiments
- > 10 Omic data types

Canonic Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products

This announcement follows successfully importing a collection of widely genetically diverse cannabis lines, establishing specialized R&D facilities, and receiving regulatory approval from the Israeli Medical Cannabis Agency (IMCA)

Rehovot, Israel – November 6, 2019 – Canonic, a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN) focused on the development of medical cannabis products, announces today the initiation of its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. The initiation of cannabis cultivation follows: (1) successfully importing widely genetically diverse cannabis lines originating from different territories, (2) establishment of cannabis dedicated R&D facilities, including greenhouses, a molecular lab and tissue culture rooms and (3) receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency (IMCA).

Canonic achieved an important milestone with the import of a genetically diverse seed collection of cannabis lines originating from different territories. These seeds were specifically selected to be the foundation of Canonic's advanced breeding program and product pipeline consisting of *MetaYield* - medical cannabis products with a stable increase of total plant active compounds, and *Precise* product line - medical cannabis with a stable increase of specific plant active compounds.

"The genomic data of the new varieties imported will be used to expand its genomic database and to be integrated in the CPB's computational platforms in order to accelerate development efforts" (Canonic PR, 6.11.2019)

Highly structured information infrastructure enabling maximization of predictive power from big data

Interconnected data hub

Plant data

Multi layered, connectivity within and across layers using proprietary functional algorithms

Genome

Transcriptome

Metabolome

Phenotypes

Clinical data *

Variety based clinical effects

	1	2	3	...	...	N
Variety 1	✓	✓	✗	✗	✗	✓
Variety 2	✓	✗	✗	✓	✗	✓
Variety ...	✗	✓	✗	✗	✓	✗
Variety N	✗	✗	✓	✓	✓	✗

* Under development

Deep understanding of causal plant-patient relationships enabled via data hub and AI methods

CANONIC

Computational analysis – utilizing artificial intelligence

Phylogeny

Gene annotation

Conservation

Expression analysis

Output

Genetic associations

Phenotypic analysis

Genetic networks

Protein structure

Identify genetic elements for Cannabis traits of interest

Design advanced breeding schemes and genetic markers

CANONIC

Plant validation

- Evogene's farm with Canonic greenhouses (including quarantine greenhouse)

- 22,000 sqf for cannabis plant development, among the largest R&D sites in Israel

- The greenhouses integrate the latest technologies for climate control, daylight control, fertilization and irrigation

- *Good Security Practice (GSP) approval and possession license for cannabis from the Israeli Medical Cannabis Agency (IMCA)*

 Confidential

Plant validation

- Molecular labs and tissue culture facilities fully equipped for cannabis R&D

- *Good Security Practice (GSP) approval and possession license for cannabis from the Israeli Medical Cannabis Agency (IMCA)*


Confidential

Agenda

Introduction

Our technology

Evogene group

Summary

CANONIC

Evogene – parent company

evogene
CPB platform

Agriculture | Human Health | Industrial Applications

100%	72%	100%	90%	100%	100%
agPlenus	lavie bio		BIOMICA	CANONIC	casterra
Ag Chemicals	**Ag Biologicals**	**Seed Traits (division)**	**Human Microbiome**	**Medical Cannabis**	**Castor Oil**
Herbicides Insecticides	Bio Stimulants Bio Pesticides	(i) Yield, ABST & Plant Disease (ii) Insect Control	Human Microbiome based Therapeutics	High yield, stability & tailored medical indications	Castor Seeds & Growth protocol

    Confidential   CANONIC

Evogene- a world leading biotech company

MISSION

We revolutionize the product development process in life-science based markets through the use of a unique Computational Predictive Biology (CPB) platform.

OUR TECHNOLOGY – THE CPB PLATFORM

Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at '**Stage Zero**'.

CPB CAPABILITIES FOR PREDICTION OF INNOVATION

- **Genetic elements** – controlling desired biological processes
- **Small molecules** – active ingredients for chemical based products
- **Microbes** – active ingredients for microbial based products

TARGET MARKETS AND CURRENT ACTIVITIES

- **Agriculture** – Ag-Chemicals, Seed Traits, Ag-Biologicals
- **Human Health** – Human Microbiome, Drug Discovery, Medical Cannabis
- **Industrial Applications** – Castor oil

CORPORATE STRUCTURE

Evogene and the CPB platform at the heart of a group of subsidiaries, each focused in different life-science based markets, with exclusive access to the CPB platform for their field of activity, providing their main competitive advantage for their product development pipeline.

FINANCIAL FUNDAMENTALS

- Cash position - $ 46 M (June 30, 2019), no debt
- Listed on TASE (2007) and NASDAQ (2013)

MAIN COLLABORATIONS WITH WORLD-LEADING COMPANIES

BASF We create chemistry   BAYER   CORTEVA agriscience   ICL

CANONIC

Agenda

Introduction

Our technology

Evogene group

Summary

CANONIC

Milestones roadmap

2019

- ✓ Establishment of R&D growing facility
- ✓ Build cannabis core collection
- ✓ Establish initial cannabis database
- Complete at least two cannabis growth cycle
- Establish agronomic protocols

2020

- First trait demonstrated
- Complete three cannabis growth cycles
- Complete establishment of proprietary cannabis database & computational infrastructure
- Expand core collection of cannabis varieties

2021

- Finalize development of first improved variety
- Pre-commercial stage
- Develop extraction & formulation process
- Analyzed clinical effect based on dedicated research

CANONIC

Summary

- **Canonic aims** to develop and bring to market medical grade cannabis through a revolutionary genomic approach

- The market is growing fast and the **main challenges** are – improving yield, stability and tailored medical products

- Using computational power (Artificial Intelligence, Big Data) to decode the cannabis genome & identify the specific genomic profiles that overcome market challenges

- We have exclusive access to **Evogene's CPB technology platform, IP and infrastructure** for the development of medical cannabis products. We harness more than 10 years of experience and reputation in plant genomics

- **Go-To-Market strategy** - Variety development through advanced breeding, seed production and seedling production, will be conducted in-house, while cultivation, formulation and distribution will be conducted through partnerships

- **Two products line**: (I) Stable enhancement of total plant compounds (II) Stable enhancement of specific active compounds

CANONIC